Lifesci Capital Has Negative Forecast for SLNO Q1 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Lifesci Capital lowered their Q1 2025 earnings per share (EPS) estimates for Soleno Therapeutics in a research report issued on Thursday, March 27th. Lifesci Capital analyst M. Belghiti now expects that the company will earn ($1.46) per share for the quarter, down from their previous forecast of ($1.43). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.84) EPS, Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.25 EPS, Q4 2026 earnings at $0.32 EPS and FY2026 earnings at ($0.47) EPS.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

A number of other analysts have also recently weighed in on the stock. Guggenheim restated a “buy” rating and issued a $81.00 price objective (up from $70.00) on shares of Soleno Therapeutics in a research note on Friday. Robert W. Baird increased their price target on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, March 27th. Stifel Nicolaus boosted their price objective on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, March 28th. Cantor Fitzgerald increased their price objective on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Finally, HC Wainwright upped their price target on shares of Soleno Therapeutics from $70.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Soleno Therapeutics currently has an average rating of “Buy” and an average target price of $98.86.

Soleno Therapeutics Price Performance

NASDAQ SLNO opened at $68.26 on Monday. The stock’s 50-day moving average is $49.82 and its two-hundred day moving average is $50.34. Soleno Therapeutics has a fifty-two week low of $36.61 and a fifty-two week high of $73.97. The firm has a market cap of $3.13 billion, a P/E ratio of -20.56 and a beta of -1.70.

Insiders Place Their Bets

In other Soleno Therapeutics news, Director Matthew Pauls sold 5,937 shares of Soleno Therapeutics stock in a transaction on Friday, March 28th. The shares were sold at an average price of $71.55, for a total transaction of $424,792.35. Following the transaction, the director now directly owns 6,500 shares of the company’s stock, valued at $465,075. The trade was a 47.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patricia C. Hirano sold 128,653 shares of the company’s stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $68.32, for a total value of $8,789,572.96. Following the completion of the transaction, the insider now owns 55,789 shares of the company’s stock, valued at $3,811,504.48. This trade represents a 69.75 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 956,250 shares of company stock worth $64,583,745. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Soleno Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in shares of Soleno Therapeutics during the 3rd quarter valued at about $262,000. Charles Schwab Investment Management Inc. increased its position in Soleno Therapeutics by 208.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 192,597 shares of the company’s stock valued at $9,724,000 after purchasing an additional 130,080 shares during the period. The Manufacturers Life Insurance Company raised its stake in Soleno Therapeutics by 6.5% in the third quarter. The Manufacturers Life Insurance Company now owns 52,634 shares of the company’s stock worth $2,657,000 after buying an additional 3,226 shares in the last quarter. FMR LLC lifted its stake in shares of Soleno Therapeutics by 6,048,754.5% in the 3rd quarter. FMR LLC now owns 665,374 shares of the company’s stock valued at $33,595,000 after purchasing an additional 665,363 shares during the period. Finally, MetLife Investment Management LLC boosted its holdings in shares of Soleno Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,772 shares of the company’s stock valued at $645,000 after buying an additional 7,196 shares in the last quarter. 97.42% of the stock is owned by hedge funds and other institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.